Company intelligence / Profile preview

Dileny Technologies

Ownership: Private
Development stage: Commercial

Overview

Developed and commercialized AI-powered medical imaging analysis tools with a focus on breast cancer risk assessment and structured reporting. Solutions have been adopted by healthcare professionals across three continents. The company was acquired by Astute Imaging in March 2022 to enhance cloud-based image-guided therapy platforms for cardiovascular and women’s health applications. No traditional clinical trial results as the products are software/AI-based.

Therapeutic areas: OtherOncologyCardiovascularWomen's Health
Modalities: Device (medical imaging software/AI platform)
Industry: Medical Imaging

Partnerships

Astute Imaging (acquirer; now integrated into their offerings)

Beyond the preview

Go deeper on Dileny Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dileny Technologies.

Explore the full profile